Clinical Trials Logo

Clinical Trial Summary

This is a prospective, non-randomized, single arm, multicenter, multinational two-stage FIH feasibility followed by pivotal study in symptomatic patients with severe aortic stenosis.


Clinical Trial Description

The study consists of 7 visits spread out across two phases over 1 year. The clinical investigation will end at 30 days post-implantation. The subsequent 3-month, 6-month and 1-year follow-up (FU) visits will thus be considered post-market clinical follow-up (PMCF). The FIH study will start by evaluating the safety and feasibility of the device and study design of the Vienna Aortic Valve SE System in 10 patients with SSAS. The FIH patients must meet all study eligibility criteria. Safety and feasibility assessments for patients in the FIH period will include implantation success, hemodynamic performance and monitoring of adverse events (AEs). Early FIH data (i.e. data from the first 10 patients to have completed visit 3 at hospital discharge) will be provided to the Data and Safety Monitoring Board (DSMB) for review during which study enrollment will be paused. After reviewing the safety results from the FIH study, the DSMB will make a recommendation on whether the study may continue as planned. FIH patients will continue to be followed up for 1 year as per protocol. Data from the 10 FIH patients and the subsequent 75 patients will be analyzed together for the pivotal study endpoints. Upon a decision from the DSMB to proceed with the study, enrolment of patients will resume. The clinical investigation phase comprises 4 visits (V1 to V4). After implantation of the IMD at visit 2, early performance and safety assessment of the device will be performed at 30 days (V4). The post-market surveillance phase comprises 3 visits (V5-V7), extending from 3 months to 1 year post-implantation, to evaluate the long-term safety and performance profile of the device. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04861805
Study type Interventional
Source P+F Products + Features GmbH
Contact Katharina Kiss, Dr
Phone +4369913289414
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date April 23, 2021
Completion date September 2022

See also
  Status Clinical Trial Phase
Completed NCT03003650 - ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis:CE-approval Cohort N/A
Active, not recruiting NCT03314857 - Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Recruiting NCT04091048 - Optimize PRO Study
Not yet recruiting NCT03247465 - Image Fusion and Calcification Raising in Trans Aortic Valve Implantation N/A
Completed NCT03143686 - ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)
Active, not recruiting NCT03466918 - Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese Population N/A
Completed NCT01819181 - Women's INternational Transcatheter Aortic Valve Implantation Registry
Recruiting NCT04331145 - Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation Phase 4
Not yet recruiting NCT02803294 - Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population Phase 3
Completed NCT02536196 - The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation N/A
Withdrawn NCT02088021 - Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access N/A
Terminated NCT02759237 - The Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance (PMS) (CoreValve India PMS) N/A
Recruiting NCT01794832 - Severe Aortic Stenosis in Patients Referred for Valve Surgery N/A
Completed NCT02424370 - Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation
Completed NCT01493284 - Portico TAVI Implant With Transfemoral Delivery System N/A
Completed NCT02664649 - Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis Phase 3
Completed NCT01487330 - First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System N/A
Recruiting NCT04722250 - SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial N/A